Cogent Biosciences, Inc. Board of Directors

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Mr. Andrew R. Robbins M.B.A.

Mr. Andrew R. Robbins M.B.A.

President, CEO & Director

Ms. Erin Schellhammer

Ms. Erin Schellhammer

Chief People Officer

Dr. Jessica Sachs M.D.

Dr. Jessica Sachs M.D.

Chief Medical Officer

Mr. Evan D. Kearns J.D.

Mr. Evan D. Kearns J.D.

Chief Legal Officer & Corporate Secretary

Mr. John L. Green C.A., CPA

Mr. John L. Green C.A., CPA

CFO & Principal Accounting Officer

Ms. Christi Waarich

Ms. Christi Waarich

Senior Director of Investor Relations

Mr. Dana R. Martin Pharm.D.

Mr. Dana R. Martin Pharm.D.

Senior VP of Medical Affairs & Chief Patient Officer

Brad Fell

Brad Fell

Senior Vice President of Chemistry

Mr. Brad Barnett

Mr. Brad Barnett

Chief Technology Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.